Clinical Trials Logo

Clinical Trial Summary

In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome. This information provides a rationale for the development of prophylactic strategies directed against chemotherapy-induced cardiotoxicity (CTIC). Activation of the renin-angiotensin system has been proved to be involved in the development and progression of cardiac dysfunction in several clinical settings, and has been suggested to have a role in the occurrence of CTIC. We investigated the role of treatment with ACE-inhibitors in the prevention of CTIC in high-risk cancer patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00292526
Study type Interventional
Source European Institute of Oncology
Contact
Status Completed
Phase Phase 4
Start date November 2000
Completion date November 2011

See also
  Status Clinical Trial Phase
Recruiting NCT05271162 - Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines Phase 3
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Recruiting NCT04092309 - Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation N/A
Recruiting NCT04790266 - Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
Enrolling by invitation NCT04305613 - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Not yet recruiting NCT05040867 - Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients N/A
Recruiting NCT05851053 - Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
Recruiting NCT05992337 - New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Enrolling by invitation NCT04877899 - Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol
Recruiting NCT05096338 - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
Recruiting NCT05078190 - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
Recruiting NCT04632407 - Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study? N/A
Completed NCT00543062 - Staccato Prochlorperazine Thorough QT/QTc Phase 1
Recruiting NCT05159479 - Defining Robust Predictors of Chemotherapy Related Cardiotoxicity
Not yet recruiting NCT06005259 - Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX) Phase 4
Recruiting NCT05406635 - Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer N/A
Recruiting NCT04047901 - Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment N/A
Terminated NCT03038997 - Early Detection of Cardiac Toxicity in Childhood Cancer Survivors
Completed NCT01246778 - Sunitinib and Atrial Trabeculae Contractility N/A